摘要
目的探讨奥氮平与齐拉西酮治疗精神分裂症的疗效及安全性。方法选择60例精神分裂症患者,分别以奥氮平10～20mg/d(30例)及齐拉西酮80～140mg/d(30例)治疗。采用阳性与阴性症状量表(PANSS)、治疗中出现的药物副反应量表(TESS),评定疗效及不良反应。结果奥氮平组有效率、显效率分别为86.6%、66.6%,与齐拉西酮组(80.0%、63.3%)比较,差异无统计学意义;奥氮平组、齐拉西酮组的不良反应发生率分别为30%、27%(P>0.05)。结论奥氮平治疗精神分裂症,对阴性症状的疗效优于齐拉西酮(P<0.01)。两药不良反应发生率均较低。
Objective To investigate the clinical efficacy and side effects of olanzapine and ziprasidone in treating schizophrenia.Methods Sixty patients were divided into olanzapine group（10~20 mg/d,n=30）and ziprasidone group（80~140 mg/d,n=30）.The clinical effects and side effects were evaluated with positive and negative symptom scales（PANSS）and treatment emergent symptom scales（TESS）.Results The effective rate and significant improved rate of olanzapine group were 86.6% and 66.6%;The effective rate and significant improved rate of ziprasidone were 80.0% and 63.3%.There was no significant difference in curative rates between the two groups（P0.05）.The side effects rates of olanzapine group and ziprasidone groups were 30.0% and 27%（P0.05）.Conclusion The effect of olanzapine is significantly better in treating negative symptom than ziprasidone（P0.01）,olanzapine has good effects on treating schizophrenia with less side effects.
出处
《实用药物与临床》
CAS
2010年第6期414-415,共2页
Practical Pharmacy and Clinical Remedies
